Lyell Immunopharma Inc (LYEL)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 12-2024 | 12-2023 | 12-2022 | 12-2021 | 12-2020 | |
| Sales | 61 | 130 | 84,683 | 10,650 | 7,756 |
| Gross Profit | 61 | 130 | 84,683 | 10,650 | 7,756 |
| Operating Expenses | 358,816 | 247,138 | 271,741 | 225,426 | 219,693 |
| Operating Income | -358,755 | -247,008 | -187,058 | -214,776 | -211,937 |
| Other Income | 15,761 | 12,376 | 3,940 | -35,443 | 7,465 |
| Pre-tax Income | -342,994 | -234,632 | -183,118 | -250,219 | -204,472 |
| Net Income Continuous | -342,994 | -234,632 | -183,118 | -250,219 | -204,472 |
| Net Income | $-342,994 | $-234,632 | $-183,118 | $-250,219 | $-204,472 |
| EPS Basic Total Ops | -26.20 | -18.60 | -14.80 | -36.80 | -313.80 |
| EPS Basic Continuous Ops | -26.23 | -18.70 | -14.82 | -36.82 | -308.45 |
| EPS Diluted Total Ops | -26.20 | -18.60 | -14.80 | -36.80 | -313.80 |
| EPS Diluted Continuous Ops | -26.23 | -18.70 | -14.82 | -36.82 | -308.45 |
| EPS Diluted Before Non-Recurring Items | -26.20 | -18.60 | -14.80 | -36.80 | N/A |
| EBITDA(a) | $-353,805 | $-236,354 | $-169,968 | $-199,251 | $-207,104 |